Lupus kidney inflammation treatment comparing obinutuzumab with steroid tablets

Trial details

Who runs it

Assistance Publique - Hôpitaux de Paris

Trial code

NCT04702256EU 2024-516242-19-00

Record updated

24 November 2025

Original description

This is a randomised, open label, controlled non-inferiority phase III multicentre trial.Read full original descriptionShow less

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

This is a randomised, open label, controlled non-inferiority phase III multicentre trial.

As primary objective, the study aims to demonstrate that a regimen free of additional oral corticosteroids but with obinutuzumab (and MMF) is non-inferior to a regimen based on oral corticosteroids and MMF in achieving the primary outcome of complete renal response at week 52 without receiving corticosteroids above a prespecified dose.

As secondary objectives, the study aims:

* To compare the efficacy of the treatments in both arms in terms of:

* partial plus complete renal response at week 52; * proteinuria < 0.8g/g at week 52; * extrarenal flares; * response as defined by a >4 points reduction in SELENA-SLEDAI score at week 52. * To compare the safety of the treatments in both arms in terms of occurrence of:

* toxicity of corticosteroids; * serious Adverse Events; * serious Infectious Episodes; * new damage. * To compare the number of patients with non-adherence to treatment in both arms. * To estimate the efficiency of obinutuzumab in this indication.

The ancillary studies will allow:

* To implement a biobank (serum, plasma, DNA, cells and urine) and a bank of renal biopsies for studies that will be part of separate research funding bids (patients will be informed that their samples and data may be used for subsequent studies and offered to consent or not). * To identify which target therapeutic levels of MMF best predicts response with least toxicity (ancillary study). * To have long term data on renal function and damage.

Inclusion: Children aged 14-17 years old and adults; Active lupus nephritis, as defined by kidney biopsy within the preceding 8 weeks, assessed by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification: class III or IV (A or A/C) ± V with active lesions in at least 10% of the viable glomeruli; Urine protein-to-creatinine ratio (uPCR) ≥ 0.5 g/g at any time in the 14 days before inclusion; No contraindications to the use of IV methylprednisolone, MMF, oral corticosteroids or obinutuzumab; Ability to provide informed consent; Willingness to use appropriate contraception, as recommended when using MMF.

Exclusion: Patients who cannot be prescribed 10 mg prednisone corticosteroids "only", after inclusion according to the physician's opinion; Prior use within 6 months of inclusion of therapeutic monoclonal antibody and/or B- or T cell modulating 'biologic' except belimumab that can be used up to 7 days before inclusion; Receipt of a live-attenuated vaccine in the 4 weeks prior to study enrolment; Active infections, including but not limited to human immunodeficiency virus (HIV), hepatitis B in the absence of a specific therapy, hepatitis C or tuberculosis; History of cervical dysplasia CIN Grade III, cervical high-risk human papillomavirus or abnormal cervical cytology other than abnormal squamous cells of undetermined significance (ASCUS) in the past 3 years in female patients. However, the patient will be eligible in the following conditions: follow-up HPV test is negative or cervical abnormality was effectively treated >1 year ago; CKD stage 4 or stage 5 defined as eGFR <30 ml/min/1.73 m2 according to CKD-EPI (to be differentiated from acute renal injury); Severe "critical" SLE flare defined as any SLE manifestation requiring more immunosuppression than allowed in the protocol, in the physician's opinion; Pregnant and breastfeeding woman; Obsolescence of >60% of the glomeruli or tubulointerstitial scarring of >60%.

ClinicalTrials.gov NCT04702256 · EU CTIS 2024-516242-19-00